Funding Opportunity PAR-21-035 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.

Notice NOT-AG-20-055 from the NIH Guide for Grants and Contracts

PhD in a medical or health science field related to the research specialty the postdoctoral job will be working in or MD/DO with appropriate clinical focus and…
From Marshfield Clinic Health System - Mon, 09 Nov 2020 19:10:59 GMT - View all Marshfield, WI jobs

Notice NOT-DE-20-037 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-039 from the NIH Guide for Grants and Contracts. The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) may not include preliminary data. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trial Required or Clinical Trial Not Allowed" FOA

Funding Opportunity PAR-21-038 from the NIH Guide for Grants and Contracts. The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) may not include preliminary data. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trials.

Competitive Salary: EMBL: Senior Java Developer (FIRE) Location: Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Genome Annotator (Regulation) Location: Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Metadata bioinformatician - European Genome-phenome Archive Cambridge, Cambridgeshire, England

Notice NOT-HD-20-038 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-008 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-007 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-006 from the NIH Guide for Grants and Contracts

Masters degree or bachelor degree with 5 years of relevant experience qualification in an appropriate science subject, molecular biology or bioinformatics is…
From Thermo Fisher Scientific - Fri, 06 Nov 2020 23:22:01 GMT - View all Charleston, WV jobs

Bioinformatics / Computer Science (preferred), Life Sciences, Business Administration, or related degree. Familiarity with genomics, Next Generation Sequencing …
From Thermo Fisher Scientific - Fri, 06 Nov 2020 23:21:30 GMT - View all Madison, WI jobs

Competitive Salary: EMBL: Postdoctoral Fellow – Birney Research (MedakaTox) Lo Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Postdoctoral Fellow – Birney Research (IndiGene) Loc Cambridge, Cambridgeshire, England

Funding Opportunity RFA-RM-21-007 from the NIH Guide for Grants and Contracts. Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund data sets, including generating hypotheses and catalyzing discoveries. Award recipients are also asked to provide feedback on the utility of the Common Fund data resources.

Funding Opportunity PAR-20-315 from the NIH Guide for Grants and Contracts. The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Funding Opportunity RFA-MD-21-001 from the NIH Guide for Grants and Contracts. This initiative will support R01 projects that test the effectiveness of multi-level interventions to prevent HIV in high-risk health disparity populations or subgroups in one or more geographic areas with a high rate of new infections.